Sunshine Biopharma has entered into a $4M at-the-market sales agreement with Aegis Capital. The agreement authorizes the firm to act as a sales agent for the offer and sale of the company's common stock.

Agreement Details

Under the terms of the agreement, Aegis Capital may sell shares of Sunshine Biopharma's common stock through "at-the-market" transactions. This method allows the company to sell shares into the trading market at prevailing market prices.

The aggregate offering price for the shares sold under the agreement will not exceed $4M. The company intends to use the net proceeds from any sales of the securities for general corporate purposes, which may include working capital and capital expenditures.

Sunshine Biopharma Inc. and the University of Arizona have published new research findings in the Journal of Medicinal Chemistry detailing the efficacy of MR1-114, a novel PLpro inhibitor, against SARS-CoV-2 variants. The study demonstrates that MR1-114 exhibits nanomolar potency in vitro against at least three variants of the virus, including the original Washington Strain, Delta, and Omicron BA.5. In vivo results from a mouse model of SARS-CoV-2 infection indicate that repeated oral administration of MR1-114 significantly suppressed pulmonary viral replication and prevented disease-associated weight loss, matching the therapeutic efficacy of Nirmatrelvir.

The research highlights MR1-114's broad-spectrum activity and desirable ADME profile, including high oral bioavailability and preferential enrichment in the lungs of mice and rats. The compound targets two vulnerabilities remote from the catalytic site of the PLpro protease: the BL2 groove and the cryptic Val70Ub pocket. This approach addresses the challenge posed by PLpro's featureless active site, which has historically hindered the development of effective inhibitors.

Key Findings from the Study

Dr. Gregory Thatcher, pharmacology professor at the University of Arizona, emphasized the importance of the support from Sunshine Biopharma in exploring antiviral agents for future outbreaks. Dr. Rui Xiong, assistant professor in the Department of Pharmacology & Toxicology, noted that MR1-114 and its analogs offer a promising new strategy for targeting PLpro and could complement existing SARS-CoV-2 antivirals.

Dr. Steve Slilaty, CEO of Sunshine Biopharma and co-author of the publication, expressed delight in collaborating with the University of Arizona researchers. He stated that the publication reflects the company's commitment to advancing science and improving patient outcomes, underscoring the potential of MR1-114 to transform the treatment landscape for SARS Coronavirus infections. The company looks forward to further exploring the compound's capabilities and clinical development.

Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada, with approximately 12 additional drugs scheduled for launch in the remainder of 2026. Its proprietary drug development program includes K1.1 mRNA for liver cancer and the PLpro protease inhibitor for SARS Coronavirus infections.